Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease.
The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 24 | 3.26 Increased by +586.57% | 1.19 Increased by +173.95% |
| Feb 27, 24 | 0.44 Increased by +163.77% | -0.03 Increased by +1.57 K% |
| Nov 2, 23 | -0.58 Increased by +9.38% | -0.69 Increased by +15.94% |
| Aug 3, 23 | -0.68 Increased by +19.05% | -0.65 Decreased by -4.62% |
| May 4, 23 | -0.67 Decreased by -55.81% | -0.73 Increased by +8.22% |
| Mar 15, 23 | -0.69 Increased by +10.39% | -0.64 Decreased by -7.81% |
| Nov 8, 22 | -0.64 Increased by +8.57% | -0.87 Increased by +26.44% |
| Aug 4, 22 | -0.84 Decreased by -21.74% | -0.93 Increased by +9.68% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -34.10 M Decreased by -13.08% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -38.46 M Increased by +5.34% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by -100.00% | -31.43 M Decreased by -51.47% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by -100.00% | -31.29 M Increased by +15.23% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -30.16 M Increased by +10.78% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 859.00 K Decreased by -62.08% | -40.63 M Decreased by -31.74% | Decreased by -4.73 K% Decreased by -247.37% |
| Mar 31, 22 | 25.72 M Increased by +315.61% | -20.75 M Increased by +13.54% | Decreased by -80.67% Increased by +79.20% |
| Dec 31, 21 | 8.62 M Increased by +52.51% | -36.91 M Decreased by -95.42% | Decreased by -428.30% Decreased by -28.13% |